ArticleCureus2025
Identifying Key Factors Influencing Non-adherence to Imatinib Therapy in Patients With Chronic Myeloid Leukemia.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Predicting adherence of imatinib in gastrointestinal stromal tumor-rise of the machines!Journal of gastrointestinal oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe effective treatment of chronic myeloid leukemia (CML) remains a challenge due to patient non-adherence to imatinib. Medication non-adherence can lead to poor treatment outcomes, increased healthcare costs, and potential development of drug resistance in patients. In this study, we aimed to assess the factors associated with non-adherence to imatinib therapy in newly diagnosed CML patients.
methodsIn this study, 82 adult patients initiated on imatinib therapy were recruited. Adherence was measured using the medication possession ratio (MPR) and visual analogue scale (VAS) at 90 days. Demographic, clinical and quality-of-life variables were assessed at baseline. Pearson's correlation and linear regression analyses were performed to identify associations and independent predictors of non-adherence, respectively.
resultsA total of 22% (18/82) of patients were non-adherent (MPR ≤ 85). Self-reported adherence via VAS correlated significantly with MPR. Among various factors, cognitive function score and occurrence of an adverse drug reaction (ADR) were associated with adherence. The impact of disease on daily life score was negatively associated with adherence. The independent predictors of adherence were role function score and impact of disease on mood score.
conclusionThis study identified cognitive and role function, impact of disease on daily life and mood and occurrence of ADR as variables influencing non-adherence to imatinib in CML patients. Early identification of these factors can guide interventions to improve adherence and treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.